Sector News

Genzyme cuts staff and announces $845m gene therapy pact

February 13, 2015
Life sciences
Sanofi’s Genzyme unit has made a major play in the gene therapy sector with a $845m alliance with Voyager Therapeutics. 
 
The announcement was made on the same day that the company unveiled 100 job cuts at its Cambridge, Massachusetts, R&D facility, including the elimination of groups focusing on cancer and certain rare diseases. 
 
The collaboration with Voyager is focusing on the develop of gene therapies based on adeno-associated virus (AAV) vectors and intended to treat central nervous system (CNS) disorders, according to the two companies. 
 
Initial targets will be Parkinson’s disease – including Voyager’s lead product candidate VY-AADC01 which has cleared preliminary clinical trials – as well as preclinical projects Friedrich’s ataxia and Huntington’s disease. Voyager is retaining rights to a programme in amyotrophic lateral sclerosis (ALS), which is also in preclinical development.
 
Genzyme is making an upfront payment of $100m to Voyager – made up of $65m in cash, a $30m equity investment and other contributions – and the gene therapy is also in line to receive development and sales milestones of up to $745m if the partnered programmes proceed as expected in the coming years. 
 
It is a major development for a company that was only launched last year with $45m in financing from venture capital firm Third Rock Ventures.
 
Genzyme brings its own expertise in gene therapy to the alliance, having been working in that area for “more than 20 years”, according to chief executive David Meeker. The company has an AAV-based gene therapy for age-related macular degeneration (AMD) in phase I trials and is also researching gene therapies for neurologic diseases, including Huntington’s.
 
“This strategic collaboration provides significant funding to drive the development of our expanded product pipeline, while also allowing Voyager to continue to thrive as an independent company,” said Steven Paul, Voyager’s CEO.
 
Oncology changes
Meanwhile, the layoffs in Cambridge include Tal Zacks, senior vice president and head of Sanofi’s global oncology division, according to a Bloomberg report, which notes that the oncology research conducted by Zacks’ team will be transferred to other R&D units in the group.
 
Sanofi made a concerted effort to build its oncology business in 2009 but has yet to reap any significant benefit from the effort.
 
The announcements come as Sanofi is still searching for a replacement for former chief executive Chris Viehbacher, who was fired last October after clashes with the company’s board of directors. 
 
Investors have become increasingly disillusioned about the as-yet fruitless search for a replacement, and Chairman Serge Weinberg said recently that a new CEO would be named by the end of March.
 
Source: PMLive

comments closed

Related News

May 17, 2024

With new partnership, Galapagos takes decentralized CAR-T manufacturing quest nationwide

Life sciences

Though Galapagos has undergone plenty of staff shake-ups and strategy revamps in recent years, the company is sticking strong to the CAR-T pivot first unveiled by CEO Paul Stoffels, M.D., following his arrival at the biotech from Johnson & Johnson in early 2022.

May 17, 2024

Sanofi invests €1 Billion to boost drug manufacturing in France

Life sciences

The new investment is expected to create more than 500 jobs and significantly strengthen France’s ability to control the production of essential medicines from start to finish, the company stated. According to Sanofi, this plan increases the amount Sanofi has committed to major projects in France since the Covid-19 pandemic to over €3.5 billion.

May 17, 2024

Lonza, busy with capacity upgrades and exec turnover, hints at CDMO industry rebound

Life sciences

A tough biotech funding environment and a downturn in COVID-related contracts has weighed heavily on CDMOs of all stripes in recent years. Now, with a new CEO waiting in the wings, Swiss manufacturing juggernaut Lonza is attempting to reassure the market that an industry stabilization is on the horizon.

How can we help you?

We're easy to reach